Gilead Sciences
Market Cap
US$85.2b
Last Updated
2020/02/20 00:12 UTC
Data Sources
Company Financials +
Executive Summary
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Good value with adequate balance sheet and pays a dividend.
Similar Companies
Share Price & News
How has Gilead Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GILD has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.8%
GILD
0.7%
US Biotechs
0.5%
US Market
1 Year Return
2.7%
GILD
15.7%
US Biotechs
20.3%
US Market
Return vs Industry: GILD underperformed the US Biotechs industry which returned 15.7% over the past year.
Return vs Market: GILD underperformed the US Market which returned 20.3% over the past year.
Shareholder returns
| GILD | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.8% | 0.7% | 0.5% |
| 30 Day | 7.5% | 2.7% | 2.0% |
| 90 Day | 3.2% | 8.7% | 9.4% |
| 1 Year | 6.7%2.7% | 16.6%15.7% | 22.8%20.3% |
| 3 Year | 7.1%-2.9% | 25.3%21.9% | 50.1%40.4% |
| 5 Year | -26.2%-35.4% | 2.8%-1.9% | 73.1%54.1% |
Price Volatility Vs. Market
How volatile is Gilead Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
12 hours ago | Simply Wall St
Could The Gilead Sciences, Inc. (NASDAQ:GILD) Ownership Structure Tell Us Something Useful?1 week ago | Simply Wall St
Is Gilead Sciences, Inc. (NASDAQ:GILD) A Strong Dividend Stock?3 weeks ago | Simply Wall St
If You Had Bought Gilead Sciences (NASDAQ:GILD) Stock Five Years Ago, You'd Be Sitting On A 40% Loss, TodayValuation
Is Gilead Sciences undervalued compared to its fair value and its price relative to the market?
23.0%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GILD ($67.35) is trading below our estimate of fair value ($87.43)
Significantly Below Fair Value: GILD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GILD is good value based on its PE Ratio (15.9x) compared to the Biotechs industry average (19.9x).
PE vs Market: GILD is good value based on its PE Ratio (15.9x) compared to the US market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: GILD is poor value based on its PEG Ratio (2.8x)
Price to Book Ratio
PB vs Industry: GILD is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Gilead Sciences forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
5.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GILD's forecast earnings growth (5.8% per year) is above the savings rate (1.7%).
Earnings vs Market: GILD's earnings (5.8% per year) are forecast to grow slower than the US market (14.2% per year).
High Growth Earnings: GILD's earnings are forecast to grow, but not significantly.
Revenue vs Market: GILD's revenue (1% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: GILD's revenue (1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GILD's Return on Equity is forecast to be high in 3 years time (21.9%)
Next Steps
Past Performance
How has Gilead Sciences performed over the past 5 years?
-30.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GILD has a high level of non-cash earnings.
Growing Profit Margin: GILD's current net profit margins (24%) are lower than last year (24.7%).
Past Earnings Growth Analysis
Earnings Trend: GILD's earnings have declined by -30.1% per year over the past 5 years.
Accelerating Growth: GILD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GILD had negative earnings growth (-1.3%) over the past year, making it difficult to compare to the Biotechs industry average (64%).
Return on Equity
High ROE: Whilst GILD's Return on Equity (23.68%) is high, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Gilead Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: GILD's short term assets ($31.5B) exceed its short term liabilities ($9.8B).
Long Term Liabilities: GILD's short term assets ($31.5B) exceed its long term liabilities ($29.2B).
Debt to Equity History and Analysis
Debt Level: GILD's debt to equity ratio (125.9%) is considered high.
Reducing Debt: GILD's debt to equity ratio has increased from 78.2% to 125.9% over the past 5 years.
Debt Coverage: GILD's debt is well covered by operating cash flow (31.3%).
Interest Coverage: GILD's interest payments on its debt are well covered by EBIT (5.1x coverage).
Balance Sheet
Inventory Level: GILD has a low level of unsold assets or inventory.
Debt Coverage by Assets: GILD's debt is covered by short term assets (assets are 1.1x debt).
Next Steps
Dividend
What is Gilead Sciences's current dividend yield, its reliability and sustainability?
4.04%
Current Dividend Yield
Upcoming Dividend Payment
Purchase Gilead Sciences before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: GILD's dividend (4.04%) is higher than the bottom 25% of dividend payers in the US market (1.44%).
High Dividend: GILD's dividend (4.04%) is in the top 25% of dividend payers in the US market (3.73%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, GILD has been paying a dividend for less than 10 years.
Growing Dividend: GILD's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (59.4%), GILD's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GILD's dividends in 3 years are forecast to be well covered by earnings (46.8% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Dan O'Day (55yo)
0.9yrs
Tenure
Mr. Daniel O'Day, also known as Dan, has been a Non-Independent Director at Galapagos NV since October 22, 2019. Mr. O'Day has been the Chairman and Chief Executive Officer of Gilead Sciences, Inc. since M ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| 0yrs | US$6.34m | 0.011% $9.4m | ||
| Chairman & CEO | 0.9yrs | no data | 0.0015% $1.3m | |
| CFO and Executive VP of Corporate Development & Strategy | 0.3yrs | no data | 0.00084% $715.7k | |
| Senior VP | 4yrs | no data | 0.00084% $715.7k | |
| Executive VP of Corporate Affairs | 4.6yrs | no data | 0.0019% $1.7m | |
| Executive Vice President of Human Resources | 0.5yrs | no data | no data | |
| Executive Vice President of Research | 19.3yrs | US$569.78k | no data | |
| Executive Vice President of Pharmaceutical Development & Manufacturing | 14.6yrs | no data | no data | |
| Senior Vice President of HIV & Emerging Viral Infections | 1.5yrs | no data | no data | |
| Executive VP & Chief Commercial Officer | 0.6yrs | no data | no data |
1.5yrs
Average Tenure
56yo
Average Age
Experienced Management: GILD's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 0.9yrs | no data | 0.0015% $1.3m | |
| Independent Director | 10.1yrs | US$449.96k | 0.0077% $6.6m | |
| Board Advisor & Director Emeritus | 0yrs | no data | no data | |
| Member of Scientific Advisory Board | 0yrs | US$16.00k | no data | |
| Independent Director | 18.3yrs | US$429.96k | 0.026% $22.0m | |
| Member of the Scientific Advisory Board | 0yrs | no data | no data | |
| Member of the Scientific Advisory Board | 0yrs | no data | no data | |
| Lead Independent Director | 6.8yrs | US$454.96k | 0.0043% $3.7m | |
| Independent Director | 3.5yrs | US$417.87k | 0.00011% $93.7k | |
| Chairperson of Scientific Advisory Board | 0yrs | no data | no data |
6.8yrs
Average Tenure
72yo
Average Age
Experienced Board: GILD's board of directors are considered experienced (6.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Gilead Sciences, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Gilead Sciences, Inc.
- Ticker: GILD
- Exchange: NasdaqGS
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$85.208b
- Shares outstanding: 1.27b
- Website: https://www.gilead.com
Number of Employees
Location
- Gilead Sciences, Inc.
- 333 Lakeside Drive
- Foster City
- California
- 94404
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GILD | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jan 1992 |
| GIS | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jan 1992 |
| GILD * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1992 |
| GIS | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1992 |
| GILD | SNSE (Santiago Stock Exchange) | Yes | Common Stock | CL | USD | Jan 1992 |
| GILD | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jan 1992 |
| 0QYQ | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 1992 |
| GILD | BIT (Borsa Italiana) | Yes | Common Stock | IT | EUR | Jan 1992 |
| GILD | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jan 1992 |
| GILD34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH REPR 1/2 COM USD0.001 | BR | BRL | Apr 2016 | |
| GILD | BASE (Buenos Aires Stock Exchange) | CEDEAR EACH 4 REP 1 COM USD0.001 | AR | ARS | Apr 2019 |
Biography
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; insitro Inc.; Nurix Therapeutics, Inc.; Lyndra Therapeutics; Carna Biosciences Inc.; Kyverna Therapeutics, Inc.; and Glympse Bio, Inc., as well as the Chengdu Hi-tech Zone. The company was founded in 1987 and is headquartered in Foster City, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/20 00:12 |
| End of Day Share Price | 2020/02/19 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.